| 001 | 168136 | ||
| 005 | 20240229133558.0 | ||
| 024 | 7 | _ | |a 10.1016/j.radonc.2021.03.014 |2 doi |
| 024 | 7 | _ | |a pmid:33753155 |2 pmid |
| 024 | 7 | _ | |a 0167-8140 |2 ISSN |
| 024 | 7 | _ | |a 1879-0887 |2 ISSN |
| 024 | 7 | _ | |a altmetric:103122382 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00704 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Rühle, Alexander |0 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |b 0 |e First author |
| 245 | _ | _ | |a Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2021 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1675086266_25376 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Mar 19;159:75-81 / #EA:E055#LA:E055# |
| 520 | _ | _ | |a As both tumor hypoxia and an immunosuppressing tumor microenvironment hamper the anti-tumor activity of radiotherapy in head-and-neck squamous cell carcinoma (HNSCC), we aimed to develop an immunohistochemistry-based hypoxia-immune classifier.39 patients receiving definitive chemoradiation for HNSCC within a prospective trial were included in this analysis. Baseline tumor samples were analyzed for the hypoxia marker carbonic anhydrase IX (CAIX) and tumor-infiltrating lymphocytes (TILs) and were correlated with [18F]-misonidazole ([18F]FMISO) PET measurements. The impact of the biomarkers on the locoregional control (LRC) was examined using Cox analyses and concordance index statistics.Low CAIX (HR=0.352, 95%CI 0.124-1.001, p=0.050) and high TIL levels (HR=0.308, 95%CI 0.114-0.828, p=0.020) were independent parameters for improved LRC and did not correlate with each other (Spearman's ρ=0.034, p=0.846). Harrell's C was 0.66 for CAIX and TIL levels alone and 0.71 for the combination. 2-year LRC was 73%, 62% and 11% for the prognostically good (CAIXlow/TILhigh), intermediate (CAIXlow/TILlow or CAIXhigh/TILhigh) and poor groups (CAIXhigh/TILlow), respectively (p=0.001). Focusing on T lymphocytes, the hypoxia-immune classifier could still stratify between favorable (CAIXlow/CD3+ TILhigh), intermediate (CAIXlow/CD3+ TILlow or CAIXhigh/CD3+ TILhigh) and poor subgroups (CAIXhigh/CD3+ TILlow) with a 2-year LRC of 80%, 59% and 14%, respectively (p=0.001). There was a positive correlation between baseline CAIX levels and [18F]FMISO SUV in week 2 of chemoradiation (ρ=0.324, p=0.050), indicating an association between higher baseline CAIX expression and tumor hypoxia persistence.We developed a clinically feasible hypoxia-immune prognostic classifier for HNSCC patients based on pre-treatment immunohistochemistry. However, external validation is required to determine the prognostic value and the potential usage for personalized radiation oncology. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Carbonic anhydrase IX |2 Other |
| 650 | _ | 7 | |a FMISO PET |2 Other |
| 650 | _ | 7 | |a Head-and-neck squamous cell carcinoma |2 Other |
| 650 | _ | 7 | |a Hypoxia |2 Other |
| 650 | _ | 7 | |a Radiotherapy biomarker |2 Other |
| 650 | _ | 7 | |a Tumor-infiltrating lymphocytes |2 Other |
| 700 | 1 | _ | |a Grosu, Anca-L |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Wiedenmann, Nicole |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Stoian, Raluca |0 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |b 3 |
| 700 | 1 | _ | |a Haehl, Erik |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Zamboglou, Constantinos |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Baltas, Dimos |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Werner, Martin |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Kayser, Gian |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Nicolay, Nils |0 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |b 9 |e Last author |
| 773 | _ | _ | |a 10.1016/j.radonc.2021.03.014 |g p. S0167814021061405 |0 PERI:(DE-600)1500707-8 |p 75-81 |t Radiotherapy and oncology |v 159 |y 2021 |x 0167-8140 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:168136 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)75b4c256a6de824414938cf2aaeff88e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2021-01-31 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-31 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-31 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b RADIOTHER ONCOL : 2019 |d 2021-01-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-01-31 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-01-31 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-31 |
| 920 | 2 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK FR zentral |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)E055-20160331 |k E055 |l E055 KKE Molekulare Radioonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E055-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::